Kami Maddocks
Overview
Explore the profile of Kami Maddocks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Phillips T, Bond D, Takiar R, Kump K, Kandarpa M, Boonstra P, et al.
Blood Adv
. 2023 Apr;
7(16):4518-4527.
PMID: 37013954
Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with a heterogeneous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently used in patients who are...
12.
Hanel W, Shindiapina P, Bond D, Sawalha Y, Epperla N, Voorhees T, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900230
Background: Relapsed or refractory classical Hodgkin lymphoma (cHL) remains a difficult treatment challenge. Although checkpoint inhibitors (CPI) have provided clinical benefit for these patients, responses are generally not durable, and...
13.
Himed S, Chung C, Dulmage B, Jaglowski S, Bond D, Maddocks K, et al.
J Eur Acad Dermatol Venereol
. 2023 Feb;
37(7):e890-e893.
PMID: 36800311
No abstract available.
14.
Faisal M, Hanel W, Voorhees T, Li R, Huang Y, Khan A, et al.
Cancer Med
. 2023 Jan;
12(7):8228-8237.
PMID: 36653918
Background: Relapsed or refractory Hodgkin lymphoma (R/R HL) is a challenging disease with limited treatment options beyond brentuximab vedotin and checkpoint inhibitors. Herein we present the time-trend analysis of R/R...
15.
Nedved A, Maddocks K, Nowakowski G
Oncologist
. 2023 Jan;
28(3):199-207.
PMID: 36648324
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 24% of new cases of B-cell non-Hodgkin lymphoma in the US each year. Up to 50% of patients relapse or are refractory...
16.
Epperla N, Switchenko J, Bachanova V, Gerson J, Barta S, Gordon M, et al.
Blood Adv
. 2022 Dec;
7(11):2287-2296.
PMID: 36516079
The prognostic relevance of diagnosis to treatment interval (DTI) in patients with newly diagnosed mantle cell lymphoma (MCL) is unknown. Hence, we sought to evaluate the impact of DTI on...
17.
Annunzio K, Cackovic M, Bond D, Sawalha Y, Voorhees T, Hanel W, et al.
Blood Adv
. 2022 Oct;
7(10):2241-2244.
PMID: 36287222
No abstract available.
18.
Fleming M, Huang Y, Dotson E, Bond D, Reneau J, Epperla N, et al.
Ther Adv Hematol
. 2022 Jul;
13:20406207221112900.
PMID: 35898434
Background: The optimal treatment of patients with systemic diffuse large B-cell (DLBCL) or high-grade B-cell (HGBL) lymphomas with synchronous central nervous system (CNS) involvement at diagnosis is not well defined....
19.
Sigmund A, Huang Y, Ruppert A, Maddocks K, Rogers K, Jaglowski S, et al.
Leukemia
. 2022 Jul;
36(8):2129-2131.
PMID: 35842461
No abstract available.
20.
Hanel W, Lata P, Youssef Y, Tran H, Tsyba L, Sehgal L, et al.
Exp Hematol Oncol
. 2022 Jul;
11(1):40.
PMID: 35831896
Background: Mantle cell lymphoma (MCL) is a rare, highly heterogeneous type of B-cell non-Hodgkin's lymphoma. The sumoylation pathway is known to be upregulated in many cancers including lymphoid malignancies. However,...